EBS on XNYS, Health Care, Emergent Biosolutions, Inc., job postings
Measures activity, not value. Not investment advice.
Quarterly revenue fell 52% to $110M, but federal contracts rose to $277.6M over 12 months.
BadNet loss of $260.7M over 12 months on $649.1M revenue
BadShort sellers hold 20% of shares, 10.1 days to cover
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $110.0M, net loss $32.7M.
31 Dec 2021RevenueNet incomeNet losstallest bar $732.9M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$110.0M
-$32.7M
30 Jun 2026
$234.3M
-$180.2M
31 Mar 2026
$156.1M
$6.8M
31 Dec 2025
$148.7M
-$54.6M
30 Sep 2025
$231.1M
$51.2M
30 Jun 2025
$140.9M
-$12.0M
31 Mar 2025
$222.2M
$68.0M
31 Dec 2024
$194.7M
–
30 Sep 2024
$293.8M
$114.8M
30 Jun 2024
$254.7M
-$283.1M
31 Mar 2024
$300.4M
$9.0M
30 Sep 2023
$270.5M
-$263.4M
30 Jun 2023
$337.9M
-$261.3M
31 Mar 2023
$165.1M
-$183.0M
31 Dec 2022
$330.2M
-$67.0M
30 Sep 2022
$240.0M
-$75.7M
30 Jun 2022
$242.7M
-$56.4M
31 Mar 2022
$307.5M
-$3.7M
31 Dec 2021
$732.9M
$193.1M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$649.1M
$788.9M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-18%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$260.7M
$75.9M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$5.02
$1.43
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
48.4%
54.5%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-27.7%
15.0%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-40.2%
9.6%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-58.2%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$188.4M
$1.4M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$175.7M
$245.5M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$514.3M
$693.1M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$338.6M
$447.6M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
1.6
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$6.09
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
0.40
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
0.92
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.83
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$146K
bought $0, sold $146K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-5.2%
183 13F filers vs 193
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
88%
45.2M shares held by 13F filers (30 Sep 2026) of 51.4M outstanding (26 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
20%
10.1M shares sold short (30 Oct 2026) of 51.4M outstanding (26 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
10.1
10.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+4.1%
9.7M shares sold short in the report before, 10.1M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
65%
65% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 53%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
29
Tracked since 21 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 21 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-52%
$110.0M vs $231.1M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-2.9%
$3.3M vs $3.4M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$277.6M
the 12 months before: $243.8M
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$2.1M
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
7
7 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
7 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.
Price $5.05 on 20 Nov 2026, -44% over 12 months (12-month range $4.45 to $13.90)
Sharp change
8-K and other filings
WARN layoff notice
Lobbying filing
Insider net buying (open market). Insiders sold a net $986K in the last 12 months (the 12 months before: -$671K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months, 0% on the 12 months before.Revenue per quarter. Revenue $110.0M in the latest quarter, -52% on a year earlier.Capital spending per quarter. Capital spending $3.3M in the latest quarter, -2.9% on a year earlier.Institutional holders (13F filers). 183 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.Federal obligations. Federal obligations: $216.6M published in the last 12 months, -24% on the 12 months before.Lobbying spend. Lobbying spend: $2.1M published in the last 12 months, -17% on the 12 months before.Workers in WARN layoff notices. Workers in WARN layoff notices: 0 published in the last 12 months.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.
Quarter ended 31 Dec 2021: $732.9M, +26% on a year earlier; public on 12 Dec 2023
Quarter ended 31 Mar 2022: $307.5M, -15% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $242.7M, -41% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $240.0M, -27% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $330.2M, -55% on a year earlier; public on 12 Dec 2023
Quarter ended 31 Mar 2023: $165.1M, -46% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $337.9M, +39% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $270.5M, +13% on a year earlier; public on 12 Dec 2023
Quarter ended 31 Mar 2024: $300.4M, +82% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $254.7M, -25% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $293.8M, +8.6% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $194.7M; public on 5 Mar 2025
Quarter ended 31 Mar 2025: $222.2M, -26% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $140.9M, -45% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $231.1M, -21% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $148.7M, -24% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $156.1M, -30% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $234.3M, +66% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $110.0M, -52% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $46.7M, +30% on a year earlier; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $32.2M, -43% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $32.1M, -52% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $27.9M, -49% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $23.6M, -49% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $15.1M, -53% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $12.5M, -61% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $12.6M, -55% on a year earlier; public on 12 Dec 2023
Quarter ended 31 Dec 2023: $11.4M, -52% on a year earlier; public on 9 Mar 2024
Quarter ended 31 Mar 2024: $10.8M, -28% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $4.6M, -63% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $5.8M, -54% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $1.7M, -85% on a year earlier; public on 5 Mar 2025
Quarter ended 31 Mar 2025: $3.6M, -67% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $2.9M, -37% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $3.4M, -41% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $3.9M, +129% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $2.4M, -33% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $2.1M, -28% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $3.3M, -2.9% on a year earlier; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 232; public on 14 Feb 2022
31 Mar 2022 report: 236; public on 16 May 2022
30 Jun 2022 report: 218; public on 15 Aug 2022
30 Sep 2022 report: 183; public on 14 Nov 2022
31 Dec 2022 report: 179; public on 14 Feb 2023
31 Mar 2023 report: 181; public on 15 May 2023
30 Jun 2023 report: 169; public on 14 Aug 2023
30 Sep 2023 report: 149; public on 14 Nov 2023
31 Dec 2023 report: 122; public on 14 Feb 2024
31 Mar 2024 report: 116; public on 15 May 2024
30 Jun 2024 report: 132; public on 14 Aug 2024
30 Sep 2024 report: 134; public on 14 Nov 2024
31 Dec 2024 report: 151; public on 14 Feb 2025
31 Mar 2025 report: 158; public on 15 May 2025
30 Jun 2025 report: 154; public on 14 Aug 2025
30 Sep 2025 report: 164; public on 14 Nov 2025
31 Dec 2025 report: 179; public on 17 Feb 2026
31 Mar 2026 report: 182; public on 15 May 2026
30 Jun 2026 report: 193; public on 14 Aug 2026
30 Sep 2026 report: 183; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $0 published
Month from 1 Dec 2021: $2.1M published
Month from 1 Jan 2022: $653K published
Month from 1 Feb 2022: -$4.4M published
Month from 1 Mar 2022: $156K published
Month from 1 Apr 2022: -$111.9M published
Month from 1 May 2022: $216K published
Month from 1 Jun 2022: $11.8M published
Month from 1 Jul 2022: $17.7M published
Month from 1 Aug 2022: $18.3M published
Month from 1 Sep 2022: $1.9M published
Month from 1 Oct 2022: $6.6M published
Month from 1 Nov 2022: $0 published
Month from 1 Dec 2022: $538K published
Month from 1 Jan 2023: $6.8M published
Month from 1 Feb 2023: $0 published
Month from 1 Mar 2023: $476K published
Month from 1 Apr 2023: $4.8M published
Month from 1 May 2023: $252.8M published
Month from 1 Jun 2023: $62.8M published
Month from 1 Jul 2023: -$5.7M published
Month from 1 Aug 2023: $60.0M published
Month from 1 Sep 2023: $20K published
Month from 1 Oct 2023: $0 published
Month from 1 Nov 2023: $75.0M published
Month from 1 Dec 2023: -$4.2M published
Month from 1 Jan 2024: $0 published
Month from 1 Feb 2024: $0 published
Month from 1 Apr 2024: $6.5M published
Month from 1 May 2024: $6.9M published
Month from 1 Jun 2024: $7.8M published
Month from 1 Jul 2024: $130.0M published
Month from 1 Aug 2024: $0 published
Month from 1 Sep 2024: $42.3M published
Month from 1 Oct 2024: -$1.1M published
Month from 1 Dec 2024: $50.0M published
Month from 1 Jan 2025: $16.7M published
Month from 1 Mar 2025: $6.7M published
Month from 1 Apr 2025: $6.9M published
Month from 1 May 2025: $0 published
Month from 1 Jun 2025: $69.3M published
Month from 1 Jul 2025: $51.9M published
Month from 1 Sep 2025: $85.0M published
Month from 1 Dec 2025: $0 published
Month from 1 Feb 2026: $0 published
Month from 1 Mar 2026: $53.7M published
Month from 1 Apr 2026: $14.4M published
Month from 1 May 2026: $11K published
Month from 1 Jun 2026: $71.7M published
Month from 1 Jul 2026: $52.8M published
Month from 1 Aug 2026: $24.0M published
Lobbying spend
Quarter from 1 Jan 2022: $550K published
Quarter from 1 Apr 2022: $1.0M published
Quarter from 1 Jul 2022: $590K published
Quarter from 1 Oct 2022: $520K published
Quarter from 1 Jan 2023: $640K published
Quarter from 1 Apr 2023: $900K published
Quarter from 1 Jul 2023: $720K published
Quarter from 1 Oct 2023: $450K published
Quarter from 1 Jan 2024: $500K published
Quarter from 1 Apr 2024: $760K published
Quarter from 1 Jul 2024: $460K published
Quarter from 1 Oct 2024: $500K published
Quarter from 1 Jan 2025: $650K published
Quarter from 1 Apr 2025: $920K published
Quarter from 1 Jul 2025: $440K published
Quarter from 1 Oct 2025: $530K published
Quarter from 1 Jan 2026: $430K published
Quarter from 1 Apr 2026: $730K published
Quarter from 1 Jul 2026: $510K published
Quarter from 1 Oct 2026: $450K published
Workers in WARN layoff notices
Month from 1 Aug 2023: 86 published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $110.0M (30 Sep 2026), 47% below its normal quarter of $208.4M; higher than 31% of its own history.
Federal obligations jump: booked $64.5M in federal contract and grant obligations in May 2026, against none in the same month last year Public on 2 Jun 2026.
Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response
$60.0Mup to $704.2M
MEDICAL COUNTERMEASURES (MCM) THAT CAN BE DEPLOYED IN THE EVENT OF A FILOVIRUS OUTBREAK ARE A CRUCIAL COMPONENT TO THE UNITED STATES GOVERNMENT?S (USG?S) OUTBREAK RESPONSE PLAN. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) IS SEEKIN
In 12 months: 3 director or officer changes, 2 major agreements, 1 agreement ended, 1 restructuring. Results releases and routine reports are left out.
29 open postings; careers site tracked since 21 Nov 2026. Most in Manufacturing & production 24%, Test, quality & reliability 17%, Finance & accounting 10%, Process engineering (semiconductor / materials) 10%.
Reported lobbying spend: $450K in Q3 2026, $510K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
31 Aug 2026
Ended
The Nickles Group, LLCfor Emergent Biosolutions
Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield. Opioid and heroin addiction legislation, naloxone access and awareness.; Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxon; S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.Budget, Health issues, Defense
Alpine Group Partners, LLC.for Emergent Biosolutions
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation,Health issues, Aviation
Ervin Graves Strategy Group, LLCfor Emergent Biosolutions Inc.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25; Opioid and heroin addictDIS
* Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act * No Specific Bill Number. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield * No SBudget, DIS, Defense, Health issues
Hecht Latham Spencer & Associates, Inc., Formerly Known As Hecht Spencer & Assocfor Emergent Biosolutions
Draft - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 - Title II - Department of Health and Human Services - funding and policy for development, acquisition, and procurement of medical countermeasures for the Strategic National StockpilHomeland security, DIS, Budget, Health issues
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, Further Extending Government Funding Act (PL 117-70); Issues related to the development, manufacture, and distribution of coronavir; Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 (117th Congress); HHealth issues, Budget
Two or more unrelated kinds of records unusual within 30 days
9 Sep 2025confirmed
Confirmed across sources Government contracts and Filings + Financials
Emergent Biosolutions(EBS): reported revenue of $140.9M for the quarter ended 30 Jun 2025, 45% below the same quarter last year, while it booked $30.0M in federal contract and grant obligations in August 2025, 28% below the same month last year. Two unrelated kinds of activity within 56 days.
Financials: Quarterly revenue change, became public on 14 Aug 2025
Government contracts: Federal obligations jump, became public on 4 Sep 2025
Government contracts: Federal obligations jump, became public on 30 Sep 2025
The quarter ended 30 Jun 2025 against the 8 quarters before it.
this quarterearliernormal: $273.6MSee the evidence (3 changes)
Financials: Quarterly revenue change became public on 14 Aug 2025
Emergent Biosolutions reported revenue of $140.9M for the quarter ended 30 Jun 2025, 45% below the same quarter last year.
This period
$140.9M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$273.6M
Typical spread (median absolute deviation)
$23.6M
How far from its usual level
-3.8
Same quarter last year
$254.7M
History used
3,378 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $273.6M
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Government contracts: Federal obligations jump became public on 4 Sep 2025
Emergent Biosolutions booked $30.0M in federal contract and grant obligations in August 2025, 28% below the same month last year.
This period
$30.0M (August 2025)
Normal month (median of 5 earlier)
$2.0M
Typical spread (median absolute deviation)
$2.0M
How far from its usual level
+9.2
Same month last year
$41.9M
History used
6,467 days
August 20255 earlier monthsnormal: $2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Government contracts: Federal obligations jump became public on 30 Sep 2025
Emergent Biosolutions booked $55.0M in federal contract and grant obligations in September 2025, 154× the same month last year.
This period
$55.0M (September 2025)
Normal month (median of 4 earlier)
$4.4M
Typical spread (median absolute deviation)
$6.4M
How far from its usual level
+5.4
Same month last year
$357K
History used
1,819 days
September 20254 earlier monthsnormal: $4.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
10 Sep 2024confirmed
Confirmed across sources Government contracts and Institutional holdings
Emergent Biosolutions(EBS): saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 2.6× the same quarter last year, while it booked $41.9M in federal contract and grant obligations in August 2024, against none in the same month last year. Two unrelated kinds of activity within 21 days.
Institutional holdings: Many funds opening a new position, became public on 14 Aug 2024
Government contracts: Federal obligations jump, became public on 5 Sep 2024
The quarter ended 30 Jun 2024 against the 8 quarters before it.
this quarterearliernormal: 19.5See the evidence (2 changes)
Institutional holdings: Many funds opening a new position became public on 14 Aug 2024
Emergent Biosolutions saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 2.6× the same quarter last year.
This period
44 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
19.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.2
Same quarter last year
17
History used
3,926 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 19.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Government contracts: Federal obligations jump became public on 5 Sep 2024
Emergent Biosolutions booked $41.9M in federal contract and grant obligations in August 2024, against none in the same month last year.
This period
$41.9M (August 2024)
Normal month (median of 5 earlier)
$2.0M
Typical spread (median absolute deviation)
$2.0M
How far from its usual level
+13.2
Same month last year
$0
History used
6,102 days
August 20245 earlier monthsnormal: $2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
31 Jul 2023confirmed
Confirmed across sources Government contracts and Layoff notices and Lobbying
Emergent Biosolutions(EBS): booked $62.9M in federal contract and grant obligations in June 2023, 5.3× the same month last year; it also lobbying on a new issue; and it filed a WARN layoff notice covering 86 workers within 30 days (Canton, MA). Three unrelated kinds of activity within 28 days.
Government contracts: Federal obligations jump, became public on 22 Jun 2023
Lobbying: Lobbying on a new issue, became public on 31 Jul 2023
Layoff notices: WARN layoff notice, became public on 9 Aug 2023
June 2023 against the 5 months before it.
this monthearliernormal: $7.4MSee the evidence (3 changes)
Government contracts: Federal obligations jump became public on 22 Jun 2023
Emergent Biosolutions booked $62.9M in federal contract and grant obligations in June 2023, 5.3× the same month last year.
This period
$62.9M (June 2023)
Normal month (median of 5 earlier)
$7.4M
Typical spread (median absolute deviation)
$6.2M
How far from its usual level
+6.0
Same month last year
$11.9M
History used
5,674 days
June 20235 earlier monthsnormal: $7.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Fires on a WARN notice after 30 days without one; notices within 30 days are summed.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
booked $64.5M in federal contract and grant obligations in May 2026, against none in the same month last year.
See the evidence
This period
$64.5M (May 2026)
Normal month (median of 5 earlier)
$323K
Typical spread (median absolute deviation)
$323K
How far from its usual level
+64.2
Same month last year
$0
History used
6,740 days
May 20265 earlier monthsnormal: $323K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
booked $53.7M in federal contract and grant obligations in March 2026, 7.7× the same month last year.
Same month last year: $6.9M; its normal month is $6.9M.
See the evidence
This period
$53.7M (March 2026)
Normal month (median of 5 earlier)
$6.9M
Typical spread (median absolute deviation)
$6.7M
How far from its usual level
+4.7
Same month last year
$6.9M
History used
6,679 days
March 20265 earlier monthsnormal: $6.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
booked $55.0M in federal contract and grant obligations in September 2025, 154× the same month last year.
Same month last year: $357K; its normal month is $4.4M.
See the evidence
This period
$55.0M (September 2025)
Normal month (median of 4 earlier)
$4.4M
Typical spread (median absolute deviation)
$6.4M
How far from its usual level
+5.4
Same month last year
$357K
History used
1,819 days
September 20254 earlier monthsnormal: $4.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
reported revenue of $140.9M for the quarter ended 30 Jun 2025, 45% below the same quarter last year, while it booked $30.0M in federal contract and grant obligations in August 2025, 28% below the same month last year. Two unrelated kinds of activity within 56 days.
See the evidence (3 changes)
Financials: Quarterly revenue change became public on 14 Aug 2025
Emergent Biosolutions reported revenue of $140.9M for the quarter ended 30 Jun 2025, 45% below the same quarter last year.
This period
$140.9M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$273.6M
Typical spread (median absolute deviation)
$23.6M
How far from its usual level
-3.8
Same quarter last year
$254.7M
History used
3,378 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $273.6M
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Government contracts: Federal obligations jump became public on 4 Sep 2025
Emergent Biosolutions booked $30.0M in federal contract and grant obligations in August 2025, 28% below the same month last year.
This period
$30.0M (August 2025)
Normal month (median of 5 earlier)
$2.0M
Typical spread (median absolute deviation)
$2.0M
How far from its usual level
+9.2
Same month last year
$41.9M
History used
6,467 days
August 20255 earlier monthsnormal: $2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Government contracts: Federal obligations jump became public on 30 Sep 2025
Emergent Biosolutions booked $55.0M in federal contract and grant obligations in September 2025, 154× the same month last year.
This period
$55.0M (September 2025)
Normal month (median of 4 earlier)
$4.4M
Typical spread (median absolute deviation)
$6.4M
How far from its usual level
+5.4
Same month last year
$357K
History used
1,819 days
September 20254 earlier monthsnormal: $4.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
4 Sep 2025Government contracts change
booked $30.0M in federal contract and grant obligations in August 2025, 28% below the same month last year.
Same month last year: $41.9M; its normal month is $2.0M.
See the evidence
This period
$30.0M (August 2025)
Normal month (median of 5 earlier)
$2.0M
Typical spread (median absolute deviation)
$2.0M
How far from its usual level
+9.2
Same month last year
$41.9M
History used
6,467 days
August 20255 earlier monthsnormal: $2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
reported revenue of $140.9M for the quarter ended 30 Jun 2025, 45% below the same quarter last year.
Same quarter last year: $254.7M; its normal quarter is $273.6M.
See the evidence
This period
$140.9M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$273.6M
Typical spread (median absolute deviation)
$23.6M
How far from its usual level
-3.8
Same quarter last year
$254.7M
History used
3,378 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $273.6M
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
booked $50.0M in federal contract and grant obligations in December 2024, against none in the same month last year.
See the evidence
This period
$50.0M (December 2024)
Normal month (median of 5 earlier)
$683K
Typical spread (median absolute deviation)
$683K
How far from its usual level
+48.7
Same month last year
$0
History used
6,224 days
December 20245 earlier monthsnormal: $683K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 2.6× the same quarter last year, while it booked $41.9M in federal contract and grant obligations in August 2024, against none in the same month last year. Two unrelated kinds of activity within 21 days.
See the evidence (2 changes)
Institutional holdings: Many funds opening a new position became public on 14 Aug 2024
Emergent Biosolutions saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 2.6× the same quarter last year.
This period
44 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
19.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.2
Same quarter last year
17
History used
3,926 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 19.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Government contracts: Federal obligations jump became public on 5 Sep 2024
Emergent Biosolutions booked $41.9M in federal contract and grant obligations in August 2024, against none in the same month last year.
This period
$41.9M (August 2024)
Normal month (median of 5 earlier)
$2.0M
Typical spread (median absolute deviation)
$2.0M
How far from its usual level
+13.2
Same month last year
$0
History used
6,102 days
August 20245 earlier monthsnormal: $2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
5 Sep 2024Government contracts change
booked $41.9M in federal contract and grant obligations in August 2024, against none in the same month last year.
See the evidence
This period
$41.9M (August 2024)
Normal month (median of 5 earlier)
$2.0M
Typical spread (median absolute deviation)
$2.0M
How far from its usual level
+13.2
Same month last year
$0
History used
6,102 days
August 20245 earlier monthsnormal: $2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 2.6× the same quarter last year.
Same quarter last year: 17; its normal quarter is 19.5.
See the evidence
This period
44 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
19.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.2
Same quarter last year
17
History used
3,926 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 19.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
booked $130.0M in federal contract and grant obligations in June 2024, 2.1× the same month last year.
Same month last year: $62.9M; its normal month is $7.4M.
See the evidence
This period
$130.0M (June 2024)
Normal month (median of 5 earlier)
$7.4M
Typical spread (median absolute deviation)
$6.2M
How far from its usual level
+13.3
Same month last year
$62.9M
History used
6,040 days
June 20245 earlier monthsnormal: $7.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Showing the newest 40 of 177 entries; narrow the window or the kind of data to see older ones.
Not listed: 342 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001367644
Ticker
EBS
Domain
emergentbiosolutions.com
Employer name
Emergent BioDefense Operations Lansing LLC, Emergent BioSolutions Inc., Emergent Product Development Gaithersburg Inc. (3 unverified)
Fein
16-1666785, 38-3412788 (2 unverified)
Hq location
MD|GAITHERSBURG|20879 (1 unverified)
Lobbying client
dotchin and associates on behalf of emergent biosolutions, emergent biosolutions, emergent biosolutions fka paxvax, emergent biosolutions formerly bracco diagnotics and 2 more
Name
400 Professional LLC, Cangene bioPharma LLC, Domestic, Emergent Acquisition Unlimited Company and 18 more
Uei
DKEFA8JAW3X4, M7ZHZ4P2MDG4, XM23STFMVML6
Wikipedia
Emergent BioSolutions
DOL H-1B labor condition applications and PERM certifications38 data points28 Oct 2019 to 28 Sep 2026
Federal lobbying disclosures (LDA)57 records, 278 data points30 Jun 1999 to 30 Sep 2026
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)235 records4 Jan 2016 to 4 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1192 data points31 Dec 2008 to 26 Oct 2026
SEC Form 4 insider transactions170 records, 536 data points4 Jan 2016 to 7 Oct 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards29 records, 1654 data points17 Dec 2007 to 18 Aug 2026
WARN layoff notices (state labor agencies)1 record, 3 data points7 Aug 2023 to 8 Aug 2023
Wikipedia pageviews11 data points11 Nov 2026 to 21 Nov 2026